Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) EBITDA (2023 - 2025)

Historic EBITDA for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to -$20.4 million.

  • Metagenomi's EBITDA fell 2089.63% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.0 million, marking a year-over-year decrease of 2508.48%. This contributed to the annual value of -$77.3 million for FY2024, which is 1347.57% down from last year.
  • Per Metagenomi's latest filing, its EBITDA stood at -$20.4 million for Q3 2025, which was down 2089.63% from -$20.2 million recorded in Q2 2025.
  • Metagenomi's EBITDA's 5-year high stood at -$10.7 million during Q2 2024, with a 5-year trough of -$25.3 million in Q1 2024.
  • For the 3-year period, Metagenomi's EBITDA averaged around -$19.2 million, with its median value being -$19.8 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 1864.38% in 2024, then plummeted by 8792.65% in 2025.
  • Quarter analysis of 3 years shows Metagenomi's EBITDA stood at -$19.0 million in 2023, then fell by 27.83% to -$24.3 million in 2024, then rose by 16.17% to -$20.4 million in 2025.
  • Its EBITDA was -$20.4 million in Q3 2025, compared to -$20.2 million in Q2 2025 and -$25.1 million in Q1 2025.